Clinical trials
Brain Injuries, Traumatic trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 2 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Australian and New Zealand Intensive Care Research Centre | 5 |
| Bayside Health | 3 |
| Neuren Pharmaceuticals Limited | 2 |
| Australia and New Zealand Intensive Care Society | 1 |
| Dr. M.K. Saxena | 1 |
| Macquarie University, Australia | 1 |
| Odyssey Group International, Inc. | 1 |
| Oragenics, Inc. | 1 |
| Phoenix Children's Hospital | 1 |
| Sydney South West Area Health Service | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Injuries, Traumatic | 18 |
| Brain Injuries | 3 |
| Hypothermia | 2 |
| Multiple Trauma | 2 |
| Wounds and Injuries | 2 |
| Brain Concussion | 1 |
| Chronic Traumatic Encephalopathy | 1 |
| Cognitive Dysfunction | 1 |
| Craniocerebral Trauma | 1 |
| Intracranial Hypertension | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.